Zydus Lifesciences gets USFDA’s final approval for Estradiol Transdermal System

18 Apr 2023 Evaluate

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) to manufacture and market Estradiol Transdermal System USP, 0.014 mg/day (weekly) (USRLD: Menostar  Transdermal System).

Estradiol transdermal system is indicated for prevention of postmenopausal osteoporosis. The drug will be manufactured at the group’s formulation manufacturing facility in Moraiya, Ahmedabad (India).

Estradiol Transdermal System USP, 0.014 mg/day (weekly) had annual sales of $1.9 million in the United States (IQVIA MAT February 2023). The group now has 363 approvals and has so far filed over 440 ANDAs since the commencement of the filing process in FY 2003-04.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.

Zydus Lifesciences Share Price

906.15 -3.85 (-0.42%)
17-Feb-2026 13:49 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1716.15
Dr. Reddys Lab 1277.80
Cipla 1342.70
Zydus Lifesciences 906.15
Lupin 2240.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×